QuantuMDx Gain Rights for Use of Nanostructures

QuantuMDx Group Ltd has signed an agreement with Nanosys Inc, an advanced materials architect, for several patents and patent applications related to the use of nanostructures for biosensors.

The core intellectual property involves the use of nanowire and nanotubes in biosensors, including field effect transistors (FETs) biosensors, which were derived from the work of Professor Charles Lieber, a professor of chemistry at Harvard, pioneer in nanotechnology, and one of the founders of Nanosys.

Under terms of the agreement, QuantuMDx Group has secured exclusive worldwide rights for the use of nanostructures for DNA sequencing and, amongst others, detecting nucleic acid biomarkers associated with
disease. In exchange, Nanosys has received an upfront license fee and downstream royalty payments. No other financial details of the deal were disclosed.

“Rapid and sensitive disease detection and DNA identification, performed at the point of care, at an affordable price point and to standards usually only seen in the referral laboratory will revolutionise care pathways in the developed world and open up a whole new standard of diagnosis in third world nations,” said Elaine Warburton, chief
Executive Officer of QuantuMDx Group.

“QuantuMDx Group is meeting this global health challenge and is currently developing several low cost assays
on our hand-held point of care device including multi-drug resistant infectious disease testing and companion diagnostics for accurate drug prescription.”

QuantuMDx Group’s Medical Director, Professor Sir John Burn, went on to say: "The technology is cheap by any measure and with turnaround times in the minutes, it will be an exciting and significant new instrument in the clinical tool box. I believe it will facilitate the wider uptake of DNA sequencing by the medical fraternity."